Seeking Referral of Patients with Non-dialysis-dependent CKD and Metabolic Acidosis

  • admin
  • 24 May 2021
  •   Comments Off on Seeking Referral of Patients with Non-dialysis-dependent CKD and Metabolic Acidosis

To Health Care Professionals:

Tricida, Inc. is conducting a randomized, placebo-controlled, Phase 3 clinical research study (VALOR-CKD) of the investigational drug veverimer (TRC101) to evaluate its efficacy and safety in delaying chronic kidney disease (CKD) progression in patients with non-dialysis-dependent CKD and metabolic acidosis. Veverimer is an investigational, once-daily, orally administered, non-absorbed polymer drug that binds and removes acid from the gastrointestinal tract.

VALOR-CKD (NCT03710291) is recruiting patients across multiple clinical trial sites in the United States. The primary endpoint of the study is progression of CKD, defined by time to first occurrence of any event in the composite endpoint consisting of a confirmed ≥ 40% reduction in eGFR, end-stage renal disease, and renal death. The trial began in November 2018 and will end when the required number of primary endpoint events have occurred.
All study assessments, study drug, and procedures will be provided at no cost to participants and participants will receive compensation for their time and study-related travel expenses. Qualifying participants are required to attend study visits approximately every 3 months.
Your patient may be eligible to participate in VALOR-CKD, if they meet the following criteria:
• Is aged 18 to 85 years.
• Is not on dialysis or post-kidney transplant.
• Has CKD with recent estimated glomerular filtration rate (eGFR) between 18 and 43 mL/min/1.73m2.
• Has low serum bicarbonate or carbon dioxide (CO2 or CO2, total) on recent metabolic/chemistry panel (< 21 mmol/L).
Study sites in your state are located in Boca Raton, Bradenton, Coral Springs, Fort Lauderdale, Hialeah, Hollywood, Miami, Miami Gardens, Miami Lakes, Pompano Beach, Port Charlotte, and Temple Terrace. Please visit for additional information.

Follow Us